

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Addiese: COMMISSIONER FOR PATENTS P O Box 1450 Alexandra, Virginia 22313-1450 www.wepto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/539,434	01/13/2006	Cinderella Christina Gerhardt	f7683 (V)	6803	
	7590 11/12/200 ATENT GROUP	8	EXAMINER		
800 SYLVAN	AVENUE		HA, J	HA, JULIE	
AG West S. W ENGLEWOOI	ing O CLIFFS, NJ 07632-3:	ART UNIT	PAPER NUMBER		
			1654		
			MAIL DATE	DELIVERY MODE	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Advisory Action Before the Filing of an Appeal Brief

periods:

Application No.	Applicant(s)
10/539,434	GERHARDT ET AL.
Examiner	Art Unit
JULIE HA	1654

--The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

IHE	E REPLY FILED <u>22 October 2008</u> FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE.
1. 🛭	🛛 The reply was filed after a final rejection, but prior to or on the same day as filing a Notice of Appeal. To avoid abandonment of this
	application, applicant must timely file one of the following replies: (1) an amendment, affidavit, or other evidence, which places the
	application in condition for allowance; (2) a Notice of Appeal (with appeal fee) in compliance with 37 CFR 41.31; or (3) a Request
	for Continued Examination (RCE) in compliance with 37 CFR 1.114. The reply must be filed within one of the following time

The period for reply expires 3 months from the mailing date of the final rejection.

The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection.

Examiner Note: If box 1 is checked, check either box (a) or (b). ONLY CHECK BOX (b) WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).

Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). NOTICE OF ADDEAL

 The Notice of Appeal was filed on <u>22 October 2008</u>. 	A brief in compliance w

ith 37 CFR 41.37 must be filed within two months of the date of filing the Notice of Appeal (37 CFR 41.37(a)), or any extension thereof (37 CFR 41.37(e)), to avoid dismissal of the appeal. Since a Notice of Appeal has been filed, any reply must be filed within the time period set forth in 37 CFR 41.37(a).

<u>AMENDMENTS</u>
3. The proposed amendment(s) filed after a final rejection, but prior to the date of filing a brief, will not be entered because
(a) ☐ They raise new issues that would require further consideration and/or search (see NOTE below);
(b) ☐ They raise the issue of new matter (see NOTE below);
(c) ☐ They are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or
(d) ☐ They present additional claims without canceling a corresponding number of finally rejected claims.
NOTE: (See 37 CFR 1.116 and 41.33(a)).
4. The amendments are not in compliance with 37 CFR 1.121. See attached Notice of Non-Compliant Amendment (PTOL-324).
5. Applicant's reply has overcome the following rejection(s):
6. Newly proposed or amended claim(s) would be allowable if submitted in a separate, timely filed amendment canceling the
non-allowable claim(s).
7. \(\sum \) For purposes of appeal, the proposed amendment(s): a) \(\sum \) will not be entered, or b) \(\sum \) will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended.
The status of the claim(s) is (or will be) as follows:
Claim(s) allowed:
Claim(s) objected to:
Claim(s) rejected: 1, 3-10, 12-13 and 15-17.
Claim(s) withdrawn from consideration:
AFFIDAVIT OR OTHER EVIDENCE
8. The affidavit or other evidence filed after a final action, but before or on the date of filing a Notice of Appeal will not be entered
because applicant failed to provide a showing of good and sufficient reasons why the affidavit or other evidence is necessary and

 The affidavit or other evidence filed after the date of filing a Notice of Appeal, but prior to the date of filing a brief, will not be entered because the affidavit or other evidence failed to overcome all rejections under appeal and/or appellant fails to provide a showing a good and sufficient reasons why it is necessary and was not earlier presented. See 37 CFR 41.33(d)(1).

10. The affidavit or other evidence is entered. An explanation of the status of the claims after entry is below or attached.

REQUEST FOR RECONSIDERATION/OTHER

11. X The request for reconsideration has been considered but does NOT place the application in condition for allowance because: Please see Continuation of 11 below.

12. Note the attached Information Disclosure Statement(s). (PTO/SB/08) Paper No(s).

13. Other:

IIHI/Anish Gupta/ Examiner, Art Unit 1654 Primary Examiner, Art Unit 1654 Continuation of 11: Claims 1, 3-10, 12-13 and 15-17 remain rejected under 35 U.S.C. 103(a) as being unpatentable over Remner et al (WO 01/37850) in view of O'Callaghan et al (WO 93/04593), as set forth in the previous office action.

Applicant argues that "the molecular weight distribution of hypoallergenic whey protein hydrolysates according to O'Callaghan (table as presented in Applicant's Arguments Page 3) clearly shows the difference between O'Callaghan and present claim. Thus, even if, as argued by the Office, it would have been obvious to a person of ordinary skill in the art to empoly a hypoallergenic whey protein hydrolysate taught by O'Callaghan in the method as taught by Petimer, this would not have ted such person to the subject method as taught by O'Callaghan it are therefor the present claims. Substitution of the whey protein hydrolysates taught by O'Callaghan et al for the Reimer et al would result in the use of a whey protein hydrolysate that does not exhibit the MW distribution profile that is recited by the present claims.

Applicant's arguments have been fully considered but have not been found persuasive, as set forth in the previous office action.

O'Callaghan teaches different ranges of whey protein hydrolysates profile. Therefore, it would have been obtate to one of ordinary skill in the art to optimize the concentrations of the whey protein profile to optimize the GLP-1 secretion and control glucose homeostasis in the subject.

Claims 1, 3-10, 12-13 and 15-17 remain provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1, 3-5, 7-9 and 19 or copending Application No. 10/519,657.